VIBI - Vilacto Bio Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0001
0.0000 (0.00%)
At close: 2:50PM EST
Stock chart is not supported by your current browser
Previous Close0.0001
Open0.0001
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0001 - 0.0002
52 Week Range0.0000 - 0.2080
Volume41,014,900
Avg. Volume42,512,736
Market Cap213,702
Beta (3Y Monthly)4.52
PE Ratio (TTM)N/A
EPS (TTM)-0.0250
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May
    PR Newswire

    OTC Markets Group Announces Lists of Compliance Downgrades and Caveat Emptor Designations for the Month of May

    NEW YORK , June 5, 2019 /PRNewswire/ --   OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the lists of downgrades from its respective ...

  • GlobeNewswire

    Vilacto Bio offering natural alternatives to strong drugs in the Psoriasis and diabetics market

    Denmark-based Vilacto Bio Inc. (OTC QB: VIBI) is happy to announce that the company has decided to introduce 2 new products and present them for the market later this summer/fall. The company will present one product for people with psoriasis and one product for people suffering from diabetes, especially skin issues related to diabetes. Regarding psoriasis we have learned that patients with this condition are seeing results after a few days’ use.

  • GlobeNewswire

    Vilacto Bio Canada Patent LACTOACTIVE® Granted

    The Company has already filed and received patents covering LACTOACTIVE® in the US, Europe and Hong Kong. The Canadian patent, when issued, is expected to give the company greater scope to continue developing the LACTOACTIVE® compound and bolster its international IP ownership position. The patent applications in Canada also cover the Company’s new compound, LACTOACTIVE iTHER®, a LACTOACTIVE® variant that offers potent immune-system enhancement with a potential for treating a wide range of diseases.

  • GlobeNewswire

    Vilacto Bio Secured Patent Applications for LACTOACTIVE®

    New York-based Vilacto Bio Inc. (OTC QB:VIBI) has secured the patent applications for LACTOACTIVE® covering rights in the US, Canada Europe and Hong Kong. Ownership of the patent applications, which Vilacto Bio had been licensing the US rights from a Danish company, is expected to give the company greater scope to continue developing the LACTOACTIVE® compound, and bolster its international IP ownership position. The patent applications also cover the company’s new compound, LACTOACTIVE iTHER®, a LACTOACTIVE® variant that offers potent immune-system enhancement with a potential for treating a wide range of diseases.